Business
Edwards Lifesciences Reaffirms Strategy for Sustainable, Differentiated Growth at Annual Investor Conference
IRVINE, Calif., December 04, 2025--Edwards Lifesciences (NYSE: EW) will outline its patient-focused strategy and share financial guidance during its annual investor conference. Entering 2026 with momentum for sustainable differentiated growth, Edwards is uniquely positioned with leading therapies across its core structural heart innovations for patients with aortic stenosis (AS), mitral regurgitation (MR), tricuspid regurgitation (TR) and pulmonic diseases, and expanding into emerging opportunit
About this update from Edwards Lifesciences Corporation
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/7686b47f20bd8889288f91d781acd6c3"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Bll6TAqvZcGXwmLkaKWz.A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/7686b47f20bd8889288f91d781acd6c3","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/9HdMptzNShLkX18k08AOyw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/7686b47f20bd8889288f91d781acd6c3","width":1024,"height":512}},"lazy":false},{"type":"text","content":"Innovation with Purpose, Powered by Science, Centered on Patients: Edwards’ Commitment to Drive Value for the Healthcare Ecosystem","length":130,"tagName":"p","attribs":{}},{"type":"text","content":"IRVINE, Calif., December 04, 2025--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) will outline its patient-focused strategy and share financial guidance during its annual investor conference. Entering 2026 with momentum for sustainable differentiated growth, Edwards is uniquely positioned with leading therapies across its core structural heart innovations for patients with aortic stenosis (AS), mitral regurgitation (MR), tricuspid regurgitation (TR) and pulmonic diseases, and expanding into emerging opportunities to advance treatments for aortic regurgitation (AR) and structural heart failure.","length":602,"tagName":"p"},{"type":"text","content":""As we enter 2026, we are poised for sustainable growth and long-term value creation," said Bernard Zovighian, Edwards’ CEO. "For the more than 20 million structural heart patients worldwide, we are continuing to bring novel and differentiated innovations and world-class evidence to transform care. In addition, we are excited to pioneer therapies for the many structural heart patient groups currently unaddressed today, such as those with asymptomatic AS and those with mitral, tricuspid or aortic regurgitation in need of a transcatheter replacement. Edwards is the only company committed to delivering first-of-its-kind innovations for all of these patients, leveraging our 65 years of leadership and valve expertise. This approach underscores our u...